



State-of-the-Art Drug Cardio-Respiratory Discovery and Development in Europe

Guest Editor:

Prof. Dr. Alice M Turner

Centre for Translational
Inflammation Research,
University of Birmingham,
Birmingham, UK

Deadline for manuscript
submissions:

closed (15 July 2022)

Message from the Guest Editor

Dear Colleagues,

This issue will focus on articles which describe all phases of drug discovery, from molecular work and early in vitro or animal studies, to clinical trials with diseases of the cardiovascular and/or respiratory system. This could include airways disease, pulmonary fibrosis, respiratory infection, ischaemic heart disease, pulmonary hypertension, cardiac failure, atrial fibrillation or other cardiorespiratory problems. Review articles about the current situation in a specific disease or disease area, which describe the landscape for treatment in the future, based on current themes in drug development, would also be of interest.

This Special Issue aims at collecting original research or review articles on Drug Cardio-respiratory Discovery and Development in Europe.

Prof. Dr. Alice M Turner

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)